EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Christiana Bardon

What's the next big thing on investors' wish list?

Burrage Capital

Darren Ji

Why Chinese investors are pouring big money into biotech

Lilly Asia Ventures

7:30 am 7:30 am (0 mins)


Registration, exhibition and breakfast

8 am 6 pm (600 mins)

Pitch and Partner

One-to-one meetings

8:30 am 10 am (90 mins)

Pitch and Partner

Pharma and large biotech presentations

Hear the latest partnering opportunities from global pharma companies.

10 am 12:15 pm (135 mins)

Pitch and Partner

Biotech presentations

8:30 am 9 am (30 mins)

Translational Impact Forum

Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development

From Bedside to Bench and Back Again: Using Clinical Data to Develop Translatable Models for Drug Discovery

8:30 am – Welcome and live broadcast start 

Speaker: James C. Foster

8:40 am – Charles River Annual Research Models in Drug Discovery Award Presentation

Speaker: Sonia Vallabh, PhD

  • Speaker James C. Foster - Chairman, President and CEO, Charles River
  • Speaker Sonia Vallabh, PhD - Prion scientist, Broad Institute; Founder, Prion Alliance

9 am 12:20 pm (200 mins)

Translational Impact Forum


9:00 am – Historical perspective on reverse translational medicine

Speaker: Elazer R. Edelman, MD, PhD

10:00 am – Break 

10:20 am – Using human metabolomic data to design animal studies

Speaker: Charles Burant, MD, PhD

11:20 am – Bedside to bench in oncology

Speaker: Jay A. Berzofsky, MD PhD

  • Speaker Jay Berzofsky, MD, PhD - Chief, Vaccine Branch, Senior Investigator Head, Molecular Immunogenetics and Vaccine Research Section, Center for Cancer Research, National Cancer Institute
  • Speaker Charles Burant, MD, PhD - Dr. Robert C. and Veronica Atkins Professor of Metabolism; Professor of Internal Medicine, Nutritional Sciences, Molecular and Integrative Physiology, University of Michigan Medical School
  • Speaker Elazer R. Edelman, MD, PhD - Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, MIT; Professor of Medicine, Harvard Medical School; Senior Attending Physician, Coronary Care Unit, Brigham and Women’s Hospital, Boston

10:15 am 11 am (45 mins)

Strategy and Business

What's the next big thing on investors' wish list?

  • Speaker Christiana Bardon - Portfolio Manager, Burrage Capital
  • Speaker Kevin Johnson - Partner, Medicxi

11:15 am 12 pm (45 mins)

Strategy and Business

Alternative financing and venture philanthropy

  • Moderator Jeffrey Quillen - Partner, Foley Hoag LLP
  • Speaker William Podd - President and CEO, Landmark Capital
  • Speaker Michael L. Salgaller - Supervisor, Invention Development and Marketing Unit, National Cancer Institute

12:15 pm 1 pm (45 mins)

Strategy and Business

Why Chinese investors are pouring big money into biotech

  • Speaker Darren Ji - Venture Partner, Lilly Asia Ventures
  • Speaker Sam Murphy - Head, International Business Development, Salubris Pharmaceuticals
  • Speaker Jimmy Wei - Venture Partner, KPCB China

1 pm 2 pm (60 mins)



1:30 pm 4:50 pm (200 mins)

Translational Impact Forum

TRACK ONE:  Approaches for rare and neglected diseases

1:30 pm – Stem cell approaches for studying inherited cardiovascular diseases

Speaker: Joseph Wu, MD, PhD

2:30 pm – Gene therapy approaches for rare disease (Batten's Disease)

Speaker: David Pearce, PhD

3:30 pm – Break

3:50 pm – Genomics in rare disease 

  • Speaker David Pearce, PhD - President of Research, Sanford Health; Senior Scientist, Children’s Health Research Center; Professor for the Department of Pediatrics, Sanford School of Medicine of the University of South Dakota
  • Speaker Joseph Wu, MD, PhD - Professor and Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD Professor of Medicine and Radiology, Stanford Cardiovascular Institute

1:30 pm 4:50 pm (200 mins)

Translational Impact Forum

TRACK TWO: Practical applications of bedside to bench reverse translation

1:30 pm – Translational medicine guide transforms drug development: The MRK experience

Speaker: Laetitia Devy-Dimanche

2:30 pm – Neurimmune reverse translational platform

Speaker: Jan Grimm, PhD

3:30 pm – Break

3:50 pm – Nordic bioscience biomarker

  • Speaker Laetitia Devy-Dimanche - Head of Global Project Management, EMD Serono
  • Speaker Jan Grimm, PhD - Chief Scientific Officer, Neurimmune

2 pm 5 pm (180 mins)

Pitch and Partner

Biotech Presentations

2 pm 2:45 pm (45 mins)

Startup Program

How to avoid VCs and still get the money you need

  • Moderator Luke Timmerman - Founder and Editor, Timmerman Report
  • Panelist Chris Garabedian - Chairman and CEO, Xontogeny
  • Panelist Peter Kolchinsky - Managing Director and Portfolio Manager, RA Capital
  • Panelist Rick Pierce - Founder, FEP Capital Advisors
  • Panelist Barbara Russell - Managing Director, Detwiler Fenton
  • Panelist James Shanahan - Co-Founder, VP Business Development, SynDevRx, Inc.

3 pm 5:30 pm (150 mins)

Startup Program

Startup pitch competition

Pitch your startup to a panel of judges comprised of business development execs, venture capitalists, and industry experts! 

Qualifying startup companies are invited to pitch their company using no more than four minutes. Our top notch panel of judges will determine the winner by the quality and effectiveness of the pitch.

  • Moderator Douglas MacDougall - President, MacDougall Biomedical Communications
  • Judge Christine Brennan - Principal, Novartis Venture Fund
  • Judge Jeremy Springhorn - Partner, Flagship Ventures
  • Judge Anna Turetsky - Associate, Lightstone Ventures
  • Judge Geeta Vemuri - Managing Partner, Agent Capital

5:30 pm 7:30 pm (120 mins)


Exhibit hall reception